Stem Cell Umbilical Cord Blood Market Report 2026

Stem Cell Umbilical Cord Blood Market Overview

• Stem Cell Umbilical Cord Blood market size has reached to $7.98 billion in 2025 • Expected to grow to $17.83 billion in 2030 at a compound annual growth rate (CAGR) of 17.4% • Growth Driver: Increasing Childbirth Rates Fueling The Growth Of Market Due To Rising Fertility And Advanced Regenerative Therapies • Market Trend: Cord Blood Therapy Gains Approval For Long Covid Treatment • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Stem Cell Umbilical Cord Blood Market?

Umbilical cord blood stem cells are special types of cells collected from the blood remaining in the umbilical cord and placenta after a baby is born. This blood is rich in hematopoietic stem cells (HSCs), which can develop into all types of blood cells, including red blood cells, white blood cells, and platelets. These stem cells are used in medical treatments such as bone marrow transplants for patients with blood-related diseases, including leukemia, lymphoma, and certain genetic disorders. The main components of the stem cell umbilical cord blood include cord blood stem cells and cord tissue stem cells. Cord blood stem cells are blood-forming stem cells collected from a newborn’s umbilical cord used to treat blood and immune disorders. The technologies utilized include cryopreservation, stem cell expansion, and cell separation, and storage services are categorized into public cord blood banks, private cord blood banks, and hybrid cord blood banks. The primary applications of stem cell umbilical cord blood include hematological disorders, metabolic diseases, immune system disorders, neurological disorders, and others, serving various end-users such as hospitals, research institutes, biotechnology companies, and others.

What Is The Stem Cell Umbilical Cord Blood Market Growth Forecast?

The stem cell umbilical cord blood market size is expected to see rapid growth in the next few years. It will grow to $17.83 billion in 2030 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to increasing demand for personalized regenerative therapies, rising investments in cell therapy research, expansion of neurological and immune disorder treatments, growing adoption of hybrid banking models, advancements in stem cell expansion technologies. Major trends in the forecast period include increasing adoption of advanced cryopreservation technologies, rising utilization of stem cells in regenerative medicine, growing expansion of private cord blood banking services, enhanced focus on cell quality and viability preservation, expansion of hybrid cord blood storage models.

Global Stem Cell Umbilical Cord Blood Market Segmentation

1) By Product Type: Cord Blood Stem Cells, Cord Tissue Stem Cells 2) By Technology: Cryopreservation, Stem Cell Expansion, Cell Separation 3) By Storage Services: Public Cord Blood Banks, Private Cord Blood Banks, Hybrid Cord Blood Banks 4) By Application: Hematological Disorders, Metabolic Diseases, Immune System Disorders, Neurological Disorders, Other Applications 5) By End-User: Hospitals, Research Institutes, Biotechnology Companies, Other End-Users Subsegments: 1) By Cord Blood Stem Cells: Hematopoietic Stem Cells, Mesenchymal Stem Cells, Endothelial Progenitor Cells, Regulatory T Cells, Natural Killer Cells, Dendritic Cells 2) By Cord Tissue Stem Cells: Mesenchymal Stem Cells, Epithelial Cells, Fibroblasts, Neural Progenitor Cells

What Is The Driver Of The Stem Cell Umbilical Cord Blood Market?

The increasing childbirth rates are expected to propel the growth of the stem cell umbilical cord blood market going forward. Childbirth rates refer to the number of live births per 1,000 people in a given population over a specific period, usually one year. The increasing childbirth rates are due to the greater availability and affordability of fertility treatments, enabling more families to have children. Umbilical cord blood stem cells are valuable for newborns as they contain hematopoietic stem cells that can be used to treat various blood, immune, and genetic disorders. These cells are a perfect genetic match for the baby and may help siblings or family members. For instance, in April 2025, according to the U.S. Centers for Disease Control and Prevention, a U.S.-based federal agency, the number of births in the USA increased from 3,596,017 in 2023 to 3,622,673 in 2024, reflecting a 1% growth. Therefore, the increasing childbirth rates are driving the growth of the stem cell umbilical cord blood industry.

Key Players In The Global Stem Cell Umbilical Cord Blood Market

Major companies operating in the stem cell umbilical cord blood market are Global Cord Blood Corporation, Vita 34 AG, Cordlife Group Limited, StemLife Berhad, MediPost Co Ltd, Smart Cells International Ltd, StemCyte Inc, Celularity Inc, Next Biosciences Pty Ltd, Esperite NV, Cryo Cell International Inc, FamiCord Group, Cells4Life Group LLP, Cryoviva Biotech Pvt Ltd, Americord Registry LLC, ViaCord LLC, China Cord Blood Corporation, CBR Systems Inc, Cord Blood Registry, LifeCell International Pvt Ltd, CryoSave India Pvt Ltd

Global Stem Cell Umbilical Cord Blood Market Trends and Insights

Major companies operating in the stem cell umbilical cord blood market are focusing on developing innovative therapies and getting approvals, such cord blood cell therapy to treat rare genetic disorders, improve immune system recovery, and support regenerative medicine applications. Cord blood cell therapy refers to the use of stem cells derived from umbilical cord blood to treat various diseases by regenerating or repairing damaged blood, immune, and other tissue systems. For instance, in October 2024, StemCyte, a US-based biotechnology company, received the regenerative medicine advanced therapy designation from the U.S. Food and Drug Administration (FDA) for hematopoietic progenitor cell cord blood therapy (HPC Cord Blood) for the treatment of Long COVID-19 syndrome. This therapy is cord blood cell therapy that utilizes stem cells from umbilical cord blood to promote healing and reduce inflammation. It has shown potential in treating immune-related and degenerative conditions, offering a non-invasive, ethically sourced option for advanced regenerative treatments.

What Are Latest Mergers And Acquisitions In The Stem Cell Umbilical Cord Blood Market?

In July 2023, Leukaemia & Myeloma Research UK, a UK-based stem cell therapies company, partnered with Smart Cells International to provide funded cord blood stem cell storage. This partnership aims to offer families a reliable and effective way to collect and store umbilical cord blood stem cells for future medical use and research. Smart Cells International is a UK-based biotechnology company that collects and stores umbilical cord blood stem cells.

Regional Outlook

North America was the largest region in the stem cell umbilical cord blood market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Stem Cell Umbilical Cord Blood Market?

The stem umbilical cord blood market consists of revenues earned by entities by providing services such as collection services, processing, testing, cryopreservation, storage, and transportation of cord blood, as well as related genetic screening and stem cell banking services. The market value includes the value of related goods sold by the service provider or included within the service offering. The stem umbilical cord blood market also includes sales of whole cord blood units, isolated stem cell products, and cord blood expansion kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Stem Cell Umbilical Cord Blood Market Report 2026?

The stem cell umbilical cord blood market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell umbilical cord blood industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.